Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results

Showing results for

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.

COVID-19 treatments in care homes

Publications

Trials

Events

Ad-hoc studentships

Oxford Trauma

Research groups

Clinical Kennedy Trust Prize Studentships

Applications for these projects are now closed. Please visit the website in summer 2026 to see available projects for October 2027 entry.

SITU

Forms library

Files Library

Study with us

Botnar projects

Applications for these projects are now closed. Please visit the website in summer 2026 to see available projects for October 2027 entry.

About us

OPEN ARMS

Jobs

Trials in closure

Trials in follow up

Trials under analysis

Trials open to recruitment

Trials in set-up

Load More

1
2
3
4
5
6
7